Can serum SCUBE1 levels be useful in the diagnosis of bladder cancer?

Abstract

Bladder cancer (BC) is the most common malignancy of the urinary system and the sixth most prevalent cancer in both men and women. There is currently no biomarker identified to facilitate the diagnosis of BC and which can be considered as the gold standard. The aim of this study was to determine the diagnostic significance of serum signal peptide-CUB-EGF domain-containing protein 1 (SCUBE1) levels in patients newly diagnosed with BC and to compare the sensitivity and specificity of SCUBE1 with those of carbonic anhydrases IX (CAIX), which has previously been shown to be positive in BC. SCUBE1 and CAIX levels were investigated using enzyme-linked immunosorbent assay (ELISA) in serum samples from 19 patients with bladder cancer and 25 healthy peers. Levels of both were significantly higher in the BC group compared with the control group (p=0.0001). Based on ROC analysis, SCUBE1 emerged as a sensitive test, similarly to CAIX, for identifying BC. These findings suggest that increased SCUBE1 levels may be a useful addition to clinical findings of disease in the diagnosis of BC patients.

Keywords

• Bladder cancer
• Carbonic anhydrase
• SCUBE1

References

1. 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020; 70: 7-30. doi: 10.3322/caac.21590.
2. 2. Batista R, Vinagre N, Meireles S, Vinagre J, Prazeres H, Leão R, Máximo V, et al. Biomarkers for bladder cancer diagnosis and surveillance: A comprehensive review. Diagnostics (Basel). 2020; 10(1): E39. doi: 10.3390/diagnostics10010039.
3. 3. Ellidag HY, Eren E, Aydin O, Akgol E, Yalcinkaya S, Sezer C, et al. Ischemia modified albumin levels and oxidative stress in patients with bladder cancer. Asian Pac J Cancer Prev. 2013; 14: 2759-63. doi: 10.7314/apjcp.2013.14.5.2759.
4. 4. Offersen BV, Knap MM, Marcussen N, Horsman MR, Hamilton-Dutoit S, Overgaard J. Intense inflammation in bladder carcinoma is associated with angiogenesis and indicates good prognosis. Br J Cancer. 2002; 87:1422-30. doi: 10.1038/sj.bjc.6600615.
5. 5. Ward C, Meehan J, Gray M, Kunkler IH, Langdon SP, Argyle DJ. Carbonic anhydrase IX (CAIX), cancer, and radiation responsiveness. Metabolites. 2018; 8(1): 13. doi: 10.3390/metabo8010013.
6. 6. Trastour C, Benizri E, Ettore F, Ramaioli A, Chamorey E, Pouysségur J, et al. HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. Int J Cancer. 2007; 120: 1451-8. doi: 10.1002/ijc.22436.
7. 7. Fidan E, Mentese A, Ozdemir F, Deger O, Kavgaci H, Karahan SC, et al. Diagnostic and prognostic significance of CA IX and suPAR in gastric cancer. Med Oncol. 2013; 30: 540. doi: 10.1007/s12032-013-0540-9.
8. 8. Topcu TO, Ozdemir F, Kavgaci H, Gunaldi M, Kocoglu H, Imamoglu GI, et al. The clinical importance of serum urokinase plasminogen activator receptor and carbonic anhydrase IX levels and the effect of anthracycline-based adjuvant chemotherapy on these biomarkers in breast cancer. J Cancer Res Ther. 2018; 14: 608-13. doi: 10.4103/0973-1482.174547.

9. 9. Karagüzel E, Menteşe A, Kazaz IO, Demir S, Örem A, Okatan AE, et al. SCUBE1: a promising biomarker in renal cell cancer. Int Braz J Urol. 2017; 43: 638-43. doi: 10.1590/S1677-5538.IBJU.2016.0316.
10. 10. Hyrsl L, Zavada J, Zavadova Z, Kawaciuk I, Vesely S, Skapa P. Soluble form of carbonic anhydrase IX (CAIX) in transitional cell carcinoma of urinary tract. Neoplasma. 2009; 56: 298. doi: 10.4149/neo_2009_04_29.
11. 11. Yang RB, Ng CKD, Wasserman SM, Colman SD, Shenoy S, Mehraban F, et al. Identification of a novel family of cell-surface proteins expressed in human vascular endothelium. J Biol Chem. 2002; 277: 46364-73. doi: 10.1074/jbc.M207410200.
12. 12. Mentese A, Fidan E, Sumer AU, Karahan SC, Sonmez M, Altay DU, et al. Is SCUBE 1 a new biomarker for gastric cancer? Cancer Biomark. 2012; 11: 191-5. doi: 10.3233/CBM-2012-00285.
13. 13. Tu CF, Yan YT, Wu SY, Djoko B, Tsai MT, Cheng CJ, et al. Domain and functional analysis of a novel platelet-endothelial cell surface protein, SCUBE1. J Biol Chem. 2008; 283: 12478-88. doi: 10.1074/jbc.M705872200.
14. 14. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol Suppl. 2016; 70: 93-105. doi: 10.1016/j.eururo.2016.02.029.
15. 15. Robins DJ, Small AC, Amin MB, Bochner BH, Chang SS, Choueiri TK, et al. MP86-17 the 2017 American Joint Committee on Cancer eighth edition cancer staging manual: changes in staging guidelines for cancers of the kidney, renal pelvis and ureter, bladder, and urethra. J Urol. 2017; 197: e1163. doi: 10.1016/j.juro.2017.02.2700.
16. 16. Bischoff CJ, Clark PE. Bladder cancer. Curr Opin Oncol. 2009; 21: 272-7. doi: 10.1097/01.cco.0000156985.47984.9e.
17. 17. Klatte T, Seligson DB, Rao JY, Yu H, de Martino M, Kawaoka K, et al. Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker. Cancer. 2009; 115: 1448-58. doi: 10.1002/cncr.24163.
18. 18. Klatte T, Belldegrun AS, Pantuck AJ. The role of carbonic anhydrase IX as a molecular marker for transitional cell carcinoma of the bladder. BJU Int. 2008; 101: 45-8. doi: 10.1111/j.1464-410X.2008.07650.x.
19. 19. Dai DF, Thajeb P, Tu CF, Chiang FT, Chen CH, Yang RB, et al. Plasma concentration of SCUBE1, a novel platelet protein, is elevated in patients with acute coronary syndrome and ischemic stroke. J Am Coll Cardiol. 2008; 51: 2173-80. doi: 10.1016/j.jacc.2008.01.060.
20. 20. Jennings LK. Mechanisms of platelet activation: need for newstrategies to protect against platelet-mediated atherothrombosis. Thromb Haemost. 2009; 102: 248-57. doi: 10.1160/TH09-03-0192.
21. 21. Sankiewicz A, Guszcz T, Mena-Hortelano R, Zukowski K, Gorodkiewicz E. Podoplanin serum and urine concentration in transitional bladder cancer. Cancer Biomark. 2016; 16: 343-50. doi: 10.3233/CBM-160572.
22. 22. Tokarzewicz A, Guszcz T, Onopiuk A, Kozlowski R, Gorodkiewicz E. Utility of cystatin C as a potential bladder tumour biomarker confirmed by surface plasmon resonance technique. Indian J Med Res. 2018; 147: 46-50. doi: 10.4103/ijmr.IJMR_124_16.
23. 23. Wang Z, Li H, Chi Q, Qiu Y, Li X, Xin L. Clinical significance of serological and urological levels of bladder cancer-specific antigen-1 (BLCA-1) in bladder cancer. Med Sci Monit. 2018; 24: 3882-7. doi: 10.12659/MSM.907075.
24. 24. Guszcz T, Szymańska B, Kozlowski R, Lukaszewski Z, Laskowski P, Gorodkiewicz E. Plasma aromatase as a sensitive and selective potential biomarker of bladder cancer and its role in tumorigenesis. Oncol Lett. 2020; 19(1): 562-8. doi: 10.3892/ol.2019.11080.
25. 25. Dirican N, Duman A, Sağlam G, Arslan A, Ozturk O, Atalay S, et al. The diagnostic significance of signal peptide-complement C1r/C1s, Uegf, and Bmp1-epidermal growth factor domain-containing protein-1 levels in pulmonary embolism. Ann Thorac Med. 2016; 11: 277-82. doi: 10.4103/1817-1737.191876.
26. 26. McMahon B, Kwaan HC. The plasminogen activator system and cancer. Pathophysiol Haemost Thromb. 2008; 36: 184-94. doi: 10.1159/000175156.
27. 27. Kvolik S, Jukic M, Matijevic M, Marjanovic K, Glavas-Obrovac L. An overview of coagulation disorders in cancer patients. Surg Oncol. 2010; 19: e33-e46. doi: 10.1016/j.suronc.2009.03.008.
28. 28. De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol. 2004; 50: 187-96. doi: 10.1016/j.critrevonc.2003.10.003.
29. 29. Turkmen S, Mentese S, Mentese A, Sumer AU, Saglam K, Yulug E, et al. The value of signal peptide-CUB-EGF domain-containing protein 1 and oxidative stress parameters in the diagnosis of acute mesenteric ischemia. Acad Emerg Med. 2013; 20: 257-64. doi: 10.1111/acem.12096.
30. 30. Ulusoy S, Ozkan G, Mentese A, Yavuz A, Karahan SC, Sumer AU. Signal peptide-CUB-EGF domain-containing protein 1 (SCUBE1) level in hemodialysis patients and parameters affecting that level. Clin Biochem. 2012; 45: 1444-9. doi: 10.1016/j.clinbiochem.2012.07.103.
31. 31. Mentese A, Yilmaz G, Sümer A, Arslan M, Karahan SC, Köksal I. The diagnostic and prognostic significance of SCUBE1 levels in Crimean-Congo hemorrhagic fever. Int J Infect Dis. 2013; 17(11): e1042-e1045. doi: 10.1016/j.ijid.2013.03.014.
32. 32. Topcu TO, Kavgaci H, Ozdemir F, Aksoy A, Erdem D, Mentese A, et al. Elevated serum levels of SCUBE1, a marker for coagulation, in patients with breast cancer. Tohoku J Exp Med. 2015; 237: 127-32. doi: 10.1620/tjem.237.127.